 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
Myriad Expects BRACAnalysis to Remain Best Seller in 'Post-Patent' Era
February 06, 2013
Myriad Expects BRACAnalysis to Remain Best Seller in 'Post-Patent' Era
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Continuing Revenue Growth in Third Quarter, Myriad Keeps Focus on Diversifying MDx Product Portfolio
May 8, 2013 / Pharmacogenomics Reporter - Integrated but Separate: Myriad Combines Comprehensive, BART BRCA Analysis; Pricing Remains Split
November 7, 2012 / Pharmacogenomics Reporter - Posting 11 Percent Revenue Growth in FY2011, Myriad Focuses on Growing MDx Pipeline
August 10, 2011 / Pharmacogenomics Reporter - Myriad Updates Investors on Companion Dx Deals, EU Expansion, and Capturing Asymptomatic Market
March 10, 2010 / Pharmacogenomics Reporter - Myriad Data Shows Reduced Rate of Variants of Unknown Significance for BRACAnalysis, Colaris Tests
June 27, 2012 / Pharmacogenomics Reporter